Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Daniele Santini¹, Sandro Barni², Salvatore Intagliata³, Alfredo Falcone⁴, Francesco Ferraù⁵, Domenico Galetta⁶, Luca Moscetti⁷, Nicla La Verde⁸, Toni Ibrahim⁹, Fausto Petrelli¹⁰, Enrico Vasile¹¹, Laura Ginocchi¹², Davide Ottaviani¹³, Flavia Longo¹⁴, Cinzia Ortega¹⁵, Antonio Russo¹⁶, Giuseppe Badalamenti¹⁷, Elena Collovà¹⁸, Gaetano Lanzetta¹⁹, Giovanni Mansueto²⁰, Vincenzo Adamo²¹, Filippo De Marinis²², Maria Antonietta Satolli²³, Flavia Cantile²⁴, Andrea Mancuso²⁵, Francesca Maria Tanca²⁶, Raffaele Addeo²⁷, Marco Russano²⁸, Michelle Sterpi²⁹, Francesco Pantano³⁰, Bruno Vincenzi³¹ & Giuseppe Tonini³²

We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer. Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis. This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.

Lung cancer is the most common solid tumor and the leading cause of human cancer deaths worldwide.¹ In the last decades the introduction of platinum-based chemotherapy, of third-generation cytotoxic drugs (such as gemcitabine, vinorelbine, docetaxel and pemetrexed), of monoclonal antibodies (such as Bevacizumab), and of novel targeted therapies has radically modified the treatment of advanced NSCLC. Consequently, median overall...
survival (OS) for patients with advanced lung cancer has increased from approximately 6 months to 12 months, and is longer for patients with driver mutations treated with targeted therapies. Nevertheless, the prognosis of NSCLC patients remains poor. In fact, the majority of cases is diagnosed at metastatic-stage.

NSCLC is the third most common cause of bone metastases (following breast and prostate cancer). The incidence of bone metastasis in this kind of tumor during the clinical course of the disease is 30–40%.6,5, and 60% of these patients present bone metastasis at the time of diagnosis. Twenty years ago it was reported that the median survival time (MST) of patients with bone metastases was 7 months.7 Moreover, survival improvement in patients affected by NSCLC may have determined a further increase in the incidence of bone metastases and in all likelihood a change in the natural history of this disease. On the other hand, the presence of bone metastases itself seems to represent a negative prognostic factor for patients affected by NSCLC.8 It is clear that in this setting, bone metastases diagnosis and treatment become a relevant clinical problem. Scientific evidence shows that bone metastases have a greater negative impact on the OS and the quality of life of patients affected by solid tumors.9,10 Indeed, bone lesions are often complicated by SREs such as: radiotherapy, pathological fractures, spinal cord compression, orthopaedic surgery and hypercalcemia. SREs cause pain and decreased quality of life, with declines in physical, functional and emotional well being and negatively affect survival11,12.

The aim of this retrospective multicenter survey was to evaluate the natural history of skeletal disease in NSCLC patients, to detect the impact of bone metastases on the outcome of the disease and to examine the role of several clinical-pathological parameters in predicting survival in these patients. Similar studies have been conducted, above all for solid tumours such as breast, prostate, kidney and colorectal cancer. On the contrary, the data about NSCLC available in literature are poor, of ambiguous interpretation and only based on small cohorts of patients.

**Patients and Methods**

**Ethics Statement.** The Ethics Committee of the coordination center has approved this multicenter retrospective observational study. Furthermore the Ethics Committee deemed unnecessary a written consent in consideration of the fact that the data the study was built on were related to patients already dead by the time it was conducted and therefore their treatment was in no way impacted or influenced by it.

The methods were carried out in accordance with the approved guidelines.

**Study design.** This retrospective, observational multicenter study included consecutive NSCLC patients with bone metastasis and was conducted in 18 Italian hospital centers in which these patients received their diagnosis and treatment from 1999 to 2012.

The data utilized pertained to NSCLC patients of all ages who were never enrolled in any clinical trials or experimental protocols and whose treatment followed the practice adopted by their respective physician. These patients were diagnosed with at least one bone metastasis during the course of their disease and their death was caused by NSCLC or cancer-related complications. More specifically, in order to be identified as having bone metastasis, at least two of the following criteria had to be fulfilled: the presence of bone metastasis was reported by the physician; the identification of bone metastases was made by body scan; a record proved the use of radiotherapy for the bone for palliative purposes; bone metastasis was detected by other imaging assessment (e.g. standard x-rays, computed tomography scans, or magnetic resonance imaging of the skeleton). The data related to each patient covers the whole course of the disease and all cancer treatments, including surgery, radiation therapy, chemotherapy and biological therapies. Assessed variables included age, histotype, number and sites of bone metastases, time to appearance of bone metastasis, times to first and subsequent SREs (from diagnosis of bone metastasis), SRE types, survival after the first SRE, survival after bone metastasis diagnosis, type and times of bisphosphonate therapy.

**Statistical analysis.** The incidence of SREs and patient demographics were determined through descriptive statistics and the Kaplan-Meier method was used to estimate all survival intervals.13 The Kaplan-Meier method was also adopted in order to describe the differences in survival that were compared through the use of the log-rank test in accordance with clinical variables or treatment.14 All the clinical parameters were evaluated as possible predictor factors for shorter time to bone metastasis, shorter time from bone metastases to SRE and shorter time from bone metastases to death by an univariate model in which all patients without a record of the date of a specific event were left censored at the date of death.

All the variables found to be significant in the univariate model were then employed in the multivariate survival analysis that was assessed by the application of the Cox proportional hazards model. Instead of using values deriving from fractions of a month, the median values were calculated from whole-month values. Finally, statistical analysis was conducted through an SPSS software (version 20.00; SPSS, Chicago, IL). To be considered statistically significant, the p value had to be under 0.05.

**Results**

**Patient characteristics.** After screening of more than 2000 patients, died from NSCLC, we identified 661 patients with bone metastasis (33%).

The median age at NSCLC diagnosis was 64 years old, range 22 to 88. Adenocarcinoma represented the most common histotype (69.3%). At the time of lung cancer diagnosis, only 20 patients had stage I disease (3.1%), 24 patients had stage II (3.7%), 48 (7.3%) stage IIIa, 45 (6.9%) IIIb and 517 (79%) stage IV. 85% of patients, at the time of diagnosis, had an ECOG PS 0–1.

The EGFR mutational analysis was unknown in 70.4% of cases; in the other 29.4% of patients, with known EGFR analysis, 74.9% was EGFR wild type and 25.1% was mutated. 18.6% of the patients went under surgical resection of primitive tumour. Most of the enrolled patients received a first-line treatment (91.7%): chemotherapy and treatment from 1999 to 2012.
chosen). In 30.6% of patients, a thirosyne-kinase inhibitor (TKI) was used (mostly in subsequent lines): gefitinib in the 22.1% of cases and erlotinib in the 77.9%. [Table 1].

Skeletal metastases and SREs. In the analyzed sample, 83.8% of patients had visceral metastasis. 57.5% of patients presented bone metastasis at the time of diagnosis. In the remaining cases, the median time to bone metastasis onset was about 9 months (range 1–73 months).

The median time to diagnosis of bone metastasis since diagnosis of NSCLC in non-metastatic patients was 19 months in patients at stage I, 21 months in patients at stage II, 12 months at stage IIIa and 10 months in patients at stage IIIb. At the time of the diagnosis of bone metastasis 50 patients had an ECOG performance status 0 (23.1% of cases); 339 patients (52.2%) had an ECOG PS 1, 134 (20.6%) ECOG PS 2 and 27 (4.2%) ECOG PS 3 (median ECOG PS was 1). In the 78.3% of cases, patients had multiple metastasis and 74.9% of them were osteolytic lesions; 11.4% osteoblastic and 14.3% of cases had mixed lesions. The axis was involved in 74.9% of cases, pelvic bones in 48.1%, limbs in 32.9%; other sites in 34.5%. 78% of patients reported bone pain at the time of bone metastasis diagnosis. The median Verbal Numerical Rating Scale (VNRS) value for pain was 4; pain value ≥ 4 was referred in the 44.3% of cases. Nevertheless skeletal pain was registered during disease course in all the patients; the median value of maximum pain was 7 (at the time of diagnosis 79.2% of patients had a VNRS value ≥ 4).

At least one SRE characterized the clinical history of 57.7% of patients out of which 42.5% had a single SRE, 11.9% had two SREs and only the 3% experimented at least 3 SREs. The most common first, second and third SRE was represented by the need of radiotherapy (in the 71.4%, 79.2% and 61.9% of cases, respectively); followed by pathologic fractures: in the 16.3%, 9.4% e 19% of SREs cases respectively [Table 2].

Table 1. Tumor characteristics and treatment.

| Tumor Characteristics And Treatments | N° Patients |
|-------------------------------------|-------------|
| **Histotype**                       |             |
| Adenocarcinoma                      | 69.3% (436) |
| Other histotypes                    | 30.7% (198) |
| **Stage**                           |             |
| I                                   | 3.1% (20)   |
| II                                  | 3.7% (24)   |
| IIIa                                | 7.3% (48)   |
| IIIb                                | 6.9% (45)   |
| IV                                  | 79% (517)   |
| **Egfr Mutation**                  |             |
| Unknown                             | 70.5% (459) |
| Known                               | 29.5% (195) |
| Wild Type                           | 74.9% (146) |
| Mutated                             | 25.1% (49)  |
| **Surgery**                         |             |
| No                                  | 81.4% (531) |
| Yes                                 | 18.6% (121) |
| **First-Line Treatment**            |             |
| Chemotherapy                        |             |
| No                                  | 5.7% (34)   |
| Yes                                 | 94.3% (564) |
| Platinum-based                      | 54.9% (388) |
| Other Therapies                     | 45.1% (265) |
| Tkis                                |             |
| No                                  | 69.4% (452) |
| Yes                                 | 30.6% (199) |
| Gefitinib                           | 22.1% (44)  |
| Erlotinib                           | 77.9% (155) |

Table 2. Most frequent first, second, third and subsequent SREs.

| SREs                     | First SRE | Second SRE | Third and subsequent SREs |
|--------------------------|-----------|------------|----------------------------|
| Radiotherapy             | 71.4% (262)| 79.2% (76) | 61.9% (13)                 |
| Pathologic fractures     | 16.3% (60) | 9.4% (9)   | 19% (4)                    |
| Spinal cord compression  | 6% (22)   | 2.1% (2)   | 9.5% (2)                   |
| Hypercalcemia            | 4.1% (15) | 4.2% (4)   | 9.5% (2)                   |
| Surgery                  | 3.3% (12) | 5.2% (5)   | 14.3% (3)                  |

The median time to diagnosis of bone metastases since diagnosis of NSCLC in non-metastatic patients was 19 months in patients at stage I, 21 months in patients at stage II, 12 months at stage IIIa and 10 months in patients at stage IIIb.
The median time to the first SRE was 6 months (range 0–57 months). 59.6% of patients received bisphosphonates. Zoledronic acid was the most used bisphosphonate (56.2% of all patients) and its administration preceded the first SRE in the 33.4% of cases. 1.4% of cases (9 patients among 661) reported osteonecrosis of the jaw (ONJ).

On Tables 3–5 we reported all parameters that showed a correlation with the time to bone metastases onset and overall survival since skeletal metastasis diagnosis, respectively in univariate and multivariate analyses. In the multivariate analysis only two parameters (advanced stage and lack of surgery) were correlated with an earlier occurrence of bone metastasis. In the multivariate analysis regarding overall survival since diagnosis of bone metastases, only five parameters remained statistically significant: histology, stage at diagnosis, platinum-based chemotherapy, the concomitant presence of visceral metastases and the use of Zoledronic acid before the first SRE onset [Tables 3–5].

Outcomes. The median overall survival from bone metastasis diagnosis was 9.5 months and the median overall survival from the first SRE was 7 months.

The median survival time in patients without SREs was 8 months; on the other hand, in patients who experienced at least one SRE was 10 months. Nevertheless, selecting the patients with an SRE as onset of bone disease, the prognosis appears to be worse than in patients who develop an SRE after diagnosis of metastases bones (OS was 6 months versus 10 months, p 0.017).

The median time between bone metastasis diagnosis and the first SRE was 14 months in biphosphonates treated patients and 7 months in patients who had not received bisphosphonates before the first SRE. The median survival from bone metastasis in patients treated with biphosphonates was 9 months and in patients that did not receive treatment was 5 months. In both cases the differences were statistically significant (p 0.01).

The concomitant presence of visceral metastases seems to be associated with a worse prognosis. The median overall survival from diagnosis of bones metastases in patients with concomitant visceral metastases was 7-months versus 10 months in patients without metastases (univariate p 0.001; multivariate P value 0.002-HR:1.354 95% C.I : 1.114-1.647).

The selective evaluation of patients with stage IV at diagnosis of NSCLC has not shown statistically significant differences in OS between patients with bone metastases and patients without bone metastases at diagnosis [Fig. 1]. Not even the time to the onset of bone metastases appears to be a factor able to predict differences in overall survival from diagnosis of bone metastases (Cox regression model; P value 0.172).

Finally, we created a score based on four factors that were found to be significant in the univariate analysis used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. According to this score, the presence of more than two of these four factors is associated with a worse prognosis: median survival was 5 months versus 8 months of the other group of patients (P value < 0.001) [Fig. 2].

Discussion
This work has the advantage of providing data from a large cohort of patients. To our knowledge, this study is the largest multicenter survey investigating the natural history of metastatic bone disease in patients with NSCLC. The high number of patients and the collection of many clinical and therapeutic parameters have enabled us to identify for each of them the correlation with the quality of life and the prognosis of these patients.

Data concerning NSCLC epidemiology are coherent with the ones found in literature such as major incidence in later age, adenocarcinoma as prevalent histotype, diagnosis of lung cancer more frequent at metastatic stage.
### Univariate Analysis

| Parameters                      | Median OS (months) | P-value | 95% CI        |
|---------------------------------|--------------------|---------|---------------|
| **Age**                         |                    |         |               |
| >64                             | 7                  | 0.008   | 6.253–7.747   |
| <64                             | 8                  |         | 7.161–8.839   |
| **ECOG PS at diagnosis**        |                    |         |               |
| 0–1                             | 8                  | 0.001   | 7.457–8.543   |
| >2                              | 3.5                | 3.080–3.920 |
| **Histology**                   |                    |         |               |
| Adenocarcinoma                  | 8                  | 0.001   | 7.099–8.901   |
| Others                          | 6                  | 5.312–6.688 |
| **Stage at diagnosis**          |                    | 0.004   |               |
| I                               | 14                 |         | 9.639–18.631  |
| II                              | 6                  |         | 2.412–9.588   |
| IIa                             | 9                  |         | 7.075–10.925  |
| IIlb                            | 9                  |         | 5.720–12.280  |
| IV                              | 7                  |         | 6.437–7.563   |
| **First-line treatment**        |                    | 0.001   |               |
| CT                              | 8                  |         | 7.463–8.537   |
| TKIs                            | 3                  |         | 2.324–3.676   |
| **Platinum-based chemotherapy** |                    |         |               |
| Yes                             | 8                  | 0.001   | 7.081–8.919   |
| No                              | 5                  | 4.089–5.911 |
| **First-line TKIs**             |                    | 0.001   |               |
| Yes                             | 12                 |         | 10.466–13.534 |
| No                              | 6                  |         | 5.395–6.605   |
| **ECOG PS at bone metastasis diagnosis** |                | 0.001   |               |
| 0–1                             | 8                  |         | 7.510–8.490   |
| >2                              | 4                  |         | 3.104–4.896   |
| **Number of SREs**              |                    | 0.001   |               |
| 0                               | 6                  |         | 5.403–6.597   |
| 1                               | 8                  |         | 7.117–8.883   |
| 2                               | 10                 |         | 7.330–12.670  |
| 3                               | 12                 |         | 7.268–17.932  |
| **Pathologic fracture**         |                    | 0.040   |               |
| Yes                             | 7                  |         | 5.026–8.974   |
| No                              | 8                  |         | 6.744–9.256   |
| **Spinal cord compression**     |                    | 0.008   |               |
| Yes                             | 7                  |         | 4.740–9.260   |
| No                              | 9                  |         | 7.864–10.136  |
| **Use of Biphosphonates**       |                    | 0.001   |               |
| Yes                             | 9                  |         | 8.046–9.954   |
| No                              | 5                  |         | 4.244–5.756   |
| **Use of Zoledronic acid**      |                    | 0.001   |               |
| Yes                             | 9                  |         | 8.120–9.880   |
| No                              | 5                  |         | 4.202–5.798   |
| **Use of Zoledronic acid before the first SRE onset** | | 0.001 |               |
| Yes                             | 10                 |         | 8.594–11.406  |
| No                              | 7                  |         | 6.358–7.642   |
| **Concomitant presence of visceral metastases** | | 0.001 |               |
| Yes                             | 7                  |         | 6.383–7.617   |
| No                              | 10                 |         | 8.277–11.722  |

**Table 4. Overall survival from bone metastasis diagnosis.** Parameters which showed statistical significativity in the univariate analysis.

### Multivariate Analysis

| Parameters                      | Median OS (months) | HR   | P-value | 95% CI        |
|---------------------------------|--------------------|------|---------|---------------|
| **Histology**                   |                    |      |         |               |
| Adenocarcinoma                  | 8                  | 1.296| 0.049   | 1.001–1.677   |
| Others                          | 6                  |      |         |               |
| **Stage at diagnosis**          |                    |      | 0.01    | 1.039–1.327   |
| I                               | 14                 | 1.17 |         | 1.039–1.327   |
| II                              | 6                  |      |         |               |
| IIa                             | 9                  |      |         |               |
| IIlb                            | 9                  |      |         |               |
| IV                              | 7                  |      |         |               |
| **Platinum-based chemotherapy** |                    |      | 0.002   | 0.511–0.861   |
| Yes                             | 8                  | 0.66 |         |               |
| No                              | 5                  |      |         |               |
| **Use of Zoledronic acid before the first SRE onset** | | 0.046 | 0.609–0.995 |
| Yes                             | 10                 | 0.77 |         |               |
| No                              | 7                  |      |         |               |
| **Concomitant presence of visceral metastases** | | 0.002 | 1.114–1.647 |
| Yes                             | 7                  | 1.354|         |               |
| No                              | 10                 |      |         |               |

**Table 5. Overall survival from bone metastasis diagnosis.** Parameters which showed statistical significativity in the multivariate analysis.
Patients with bone metastases treated with TKIs or Bevacizumab as first-line treatment had better survival rates compared with those treated with only chemotherapy. This finding confirms and emphasizes the use of biological drugs in this setting of patients.

Clinical data show that pain is the most observed symptom, affecting almost every patient at the moment of bone metastasis diagnosis, and all patients during the clinical course of the disease. Considering bone pain and performance status (which is worsened by the onset of bone metastases in approximately 17% of patients) as parameters for measuring the quality of life, we can assume that skeletal metastases significantly impact the quality of life of the patients. Our study did not evaluate the impact of the analgesic therapy, although it is clear that an adequate pain management is extremely important for these patients. Specific studies on this matter are needed to identify the correct management of bone pain in patients with NSCLC.

Bone metastases are more frequently multiple and osteolytic and can affect any segment of the skeleton, mainly the spine followed by long and pelvic bones. Skeletal complications occur in more than half of the cases. Radiation therapy is the most common SRE since it is one of the main tools to relieve pain which is the predominant symptom in these patients. Hypercalcemia, according to other studies, is reported in 12–20% of patients with lung cancer\textsuperscript{15}. In our study it is present in a lower percentage (3%, 20/661 patients). This discrepancy could be due to the fact that the evidence already present in literature reports the incidence of hypercalcemia in all patients with lung cancer, whereas in our study we enrolled only patients with NSCLC and bone metastases treated mostly with bisphosphonates.

The median survival time in patients without SREs was lower than in patients who experimented at least one SRE therefore it seems plausible to assume that the presence of skeletal events is a favorable prognostic factor. This finding is in disagreement with similar analysis conducted for other solid tumors, including studies regarding Lung Cancer; however these analyses were carried on a much lower number of patients compared to our study\textsuperscript{15}. Our hypothesis is that this inconsistency can be explained by the prolonged survival of patients with NSCLC registered in recent years. Namely, patients who live longer have a greater chance of developing SRES.

Figure 1. IV stage at diagnosis: patients with or without bone metastases. Kaplan-Meier survival analysis.

Figure 2. Score to predict a different prognosis at diagnosis of bone metastases. Kaplan-Meier survival analysis.
Conversely, patients with an SRE as onset of bone disease have a worse prognosis than those who develop an SRE after diagnosis of metastases bones. These data would suggest the possible existence of two different types of skeletal disease secondary to NSCLC: one particularly aggressive where the presence of SRE (especially if manifested as onset of bone disease) is associated with a worse prognosis, and an other, less aggressive, in which increased survival is associated with an increased risk of developing SREs.

Bisphosphonates were proven to delay by 7 months the first SRE after diagnosis of bone metastases compared to untreated patients (14 vs. 7 months) (P value 0.003). Regarding survival rates, bisphosphonates appear to correlate with increased survival (9 vs 5 months) (P value 0.006). However, this data may be the result of a selection bias, since bisphosphonates are administered to patients with good life expectancy and also a consequence of the retrospective nature of this analysis.

The role of these agents in the treatment of advanced NSCLC has not been investigated in a large phase III trial. Nevertheless, Rosen et al. showed the long-term efficacy of zoledronic acid in the treatment of skeletal metastasis in patients with NSCLC. The results of our study would confirm these findings and would encourage the use of bisphosphonates in this setting of patients. Furthermore, denosumab is a new bone-targeted therapy. Its efficacy is documented in patients with bone metastases arising from solid tumors (including NSCLC). Patients included in our study did not receive denosumab because they were retrospectively enrolled before this drug started to be used in this setting.

Limitations of our study include its retrospective design and inclusion of an unselected heterogeneous cohort of patients with all types of histological (squamous, adenocarcinoma, large cell, undifferentiated) variants of NSCLC, molecular subclassifications (EGFR, ALK, ROS-1, etc) as well as a wide range of anticancer therapies. However, the types of patients included in this study represent the typical scenario of real clinical practice. Another limitation is the heterogeneity of standardized methods used for detecting bone metastases, with each methodology having its own limit of detection.

Nonetheless, we believe that this study will enhance the knowledge of the natural history of NSCLC with bone metastases and will aid to identify some parameters that have a real prognostic value in this setting of patients. Furthermore, it has helped in providing a score that may be used in clinical practice, if validated in other pools of patients, to recognize patients with different outcomes at the time of skeletal disease diagnosis.

Further studies, especially prospective ones regarding the treatment of bone pain and specific treatments of bone metastases (bisphosphonates, denosumab, radiotherapy) are required and could offer interesting perspectives on how to improve not only the quality of life but also the survival of patients affected by NSCLC with bone metastases.

References

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer Statistics, 2014. CA Cancer J Clin 64, 9–29 (2014)
2. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355, 2542–50 (2006)
3. Johnson, B. E. et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol ASCO Annual Meeting Abstracts. 31, 8019 (2013)
4. Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. A randomised, Phase III, double blind, placebo-controlled trial. Cancer. 100, 2613–2621 (2004).
5. Price, N., Belani, C. P. & Jain, V. K. Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer. 5, 267–269 (2004)
6. Kosteva, J. & Langer, C. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer. 46 (Suppl 1), S45 (2004)
7. Coleman, R. E. Skeletal complications of malignancy. Cancer. 890, 1588–94. doi: 10.1002/(SICI)1097-0142(19971015) (1997)
8. O’Connell, J. P. et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 4, 1604–14 (1986)
9. Weinfurt, K. P. et al. The significance of skeletal related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 16, 579–584 (2005)
10. Lipton, A. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: long term follow-up of two randomized, placebo-controlled trials. Cancer. 88, 1082–1090 (2000).
11. Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27, 165–176 doi: 10.1053/CTRV.2000.0210 (2011).
12. Coleman, R. E. Bisphosphonates: clinical experience. Oncologist. 9 (Suppl 4), 14–27 (2004)
13. Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53, 457–481 doi: 10.1080/01621459.1958.10501452 (1958)
14. Petri, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 35, 1–39. (1977)
15. Tsuya, A., Kurata, T., Tamura, K. & Fukushima, M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 57, 229–232 (2007)
16. Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double blind, placebo-controlled trial. Cancer. 100, 2613–2621 (2004).
17. Scagliotti, G. V. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid. Subgroup analysis from a randomized phase 3 study. J Thoracic Oncol. 7, 1823–1829 (2012).

Acknowledgements

Sterpi M. made a substantial contribution to the revision of the final version of the manuscript.

Author Contributions

D.S., S.I. and M.R. wrote the main manuscript. M.R. and F.P. prepared tables and figures. D.S., S.B., S.I., A.F., F.F., D.G., L.M., N.L.V., T., F.P., E.V., L.G., D.O., F.L., C.O., A.R., G.B., E.C., G.L., G.M., V.A., F.D.M., M.A.S., F.C., A.M., F.M.T., R.A., M.R., F.P. and G.T. made substantial contributions to concept and design of the study, revised the manuscript and gave their approval to the final version of the manuscript.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Santini, D. et al. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci. Rep. 5, 18670; doi: 10.1038/srep18670 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Daniele Santini, Sandro Barni, Salvatore Intagliata, Alfredo Falcone, Francesco Ferràù, Domenico Galetta, Luca Moscetti, Nicla La Verde, Toni Ibrahim, Fausto Petrelli, Enrico Vasile, Laura Ginocchi, Davide Ottomanì, Flavia Longo, Cinzia Ortega, Antonio Russo, Giuseppe Badalamenti, Elena Collovà, Gaetano Lanzetta, Giovanni Mansueto, Vincenzo Adamo, Filippo De Marinis, Maria Antonietta Satolli, Flavia Cantile, Andrea Mancuso, Francesca Maria Tanca, Raffaele Addeo, Marco Russano, Michelle Sterpi, Francesco Pantano, Bruno Vincenzi & Giuseppe Tonini

Scientific Reports 5:18670; doi: 10.1038/srep18670; published online 22 December 2015; updated on 15 April 2016

The original version of this Article contained errors in the spelling of the authors Daniele Santini, Sandro Barni, Salvatore Intagliata, Alfredo Falcone, Francesco Ferràù, Domenico Galetta, Luca Moscetti, Nicla La Verde, Toni Ibrahim, Fausto Petrelli, Enrico Vasile, Laura Ginocchi, Davide Ottomanì, Flavia Longo, Cinzia Ortega, Antonio Russo, Giuseppe Badalamenti, Elena Collovà, Gaetano Lanzetta, Giovanni Mansueto, Vincenzo Adamo, Filippo De Marinis, Flavia Cantile, Andrea Mancuso, Raffaele Addeo, Marco Russano, Michelle Sterpi, Francesco Pantano, Bruno Vincenzi and Giuseppe Tonini which were incorrectly given as Santini Daniele, Barni Sandro, Intagliata Salvatore, Falcone Alfredo, Ferràù Francesco, Galetta Domenico, Moscetti Luca, La Verde Nicla, Ibrahim Toni, Petrelli Fausto, Vasile Enrico, Ginocchi Laura, Ottomanì Davide, Longo Flavia, Ortega Cinzia, Russo Antonio, Badalamenti Giuseppe, Collovà Elena, Lanzetta Gaetano, Mansueto Giovanni, Adamo Vincenzo, De Marinis Filippo, Cantile Flavia, Mancuso Andrea, Addeo Raffaele, Russano Marco, M Sterpi, Pantano Francesco, Vincenzi Bruno and Tonini Giuseppe respectively.

The Author Contributions Statement,

“S.D., I.S. and R.M. wrote the main manuscript. R.M. and P.F. prepared tables and figures. S.D., B.S., I.S., F.A., F.F., G.D., M.L., L.V.N., I.T., P.F., V.E., G.L., O.D., I.F., O.C., R.A., B.E., C.E., I.G., M.G., A.V., D.M.F., S.M.A., C.F., M.A., T.F.M., A.R., R.M., P.F., V.B. and T.G. made substantial contributions to concept and design of the study, revised the manuscript and gave their approval to the final version of the manuscript.”

now reads,

“D.S., S.I. and M.R. wrote the main manuscript. M.R. and F.P. prepared tables and figures. D.S., S.B., S.I., A.F., F.F., D.G., L.M., N.L.V., T.I., F.P., E.V., L.G., D.O., F.L., C.O., A.R., G.B., E.C., G.L., G.M., V.A., F.D.M., M.A.S., F.C., A.M., F.M.T., R.A., M.R., F.P., B.V. and G.T. made substantial contributions to concept and design of the study, revised the manuscript and gave their approval to the final version of the manuscript.”

In addition, the 'How to cite this article' section quoted an incorrect abbreviation for Daniele Santini.

These errors have now been corrected in the PDF and HTML versions of the Article.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/